Spyros Artavanis-Tsakonas, Ph.D.
Professor Spyros Artavanis-Tsakonas, a molecular biologist and developmental geneticist, is Professor Emeritus in the Department of Cell Biology at Harvard Medical School, which he joined in 1998. He is the founding Director of the Developmental and Regenerative Biology Program at Harvard Medical School. From 1999-2007 he was also the Isselbacher-Schwartz Professor at Massachusetts General Hospital Cancer Center.
He completed his undergraduate studies in chemistry at the Swiss Federal Institute of Technology, ETH in Zurich before earning his Ph.D. from Cambridge University for work carried out at the MRC Laboratory of Molecular Biology. After postdoctoral work at the Biozentrum in Basel and at Stanford University, he joined the Yale faculty in 1981. He was appointed Professor in the Department of Biology in 1989 and then, concurrently, Professor at the Department of Cell Biology at the Yale School of Medicine. He also served as the Director of the Biological Sciences Division at Yale.
He was a Howard Hughes Medical Institute Investigator from 1987 to 1998 when he left for Harvard, where he was appointed Professor of Cell Biology. In 1999, concurrently, he was elected Professor at the Collège de France, in Paris, holding the Chair of Biology and Genetics of Development until 2012 when he became Professeur honoraire. He is the Founding Director of the Department of Genetics and Developmental Biology at Institut Curie, Paris, 2007-2009.
From 2012 to March 2017 he served as Chief Scientific Officer and Executive Vice President at Biogen.
His laboratory has been studying cellular interactions in development and disease and pioneered the use of genetic and molecular approaches to define and analyze the Notch signaling pathway. Currently, at his Harvard Medical School laboratory, he is using genetic tools to dissect neurodegeneration pathways related to human disease and is completing work defining the Drosophila Proteome.
Professor Artavanis-Tsakonas is a fellow of the American Academy of Arts and Sciences, an associate member of EMBO, and a corresponding member of the Academy of Athens.
Ms. Fulla Chapple is Executive Director of Fondation Santé. She joined the foundation in 2001 and is responsible for institutional development and coordinating all programmatic activities.
Ms. Chapple has extensive experience in working for non-profit organizations in various capacities. Before joining Fondation Santé she served as Fundraising Consultant for the UNHCR (United Nations High Commissioner for Refugees – Athens Branch Office). For several years she served as Head of Fundraising and Communications for the Greek office of the World Wide Fund for Nature (WWF Greece). She also worked for Emporiki Venture Capital, where she was responsible for the management and administration of the company’s regional offices in Eastern Europe and the Balkans.
Ms. Chapple began her career in London as a Conference Manager at The Conference Associates Ltd., and then as the owner and director of the Athens Conference Center, in Greece, which she managed for 15 years. Ms. Chapple holds a B.Sc. in business administration from The American College of Greece.
Stelios Papadopoulos, Ph.D.
Chairman of the Board and Treasurer
Dr. Stelios Papadopoulos is a co-founder and Chairman/Treasurer of Fondation Santé. He is also Chairman of the Board of Directors of Biogen, Inc., Exelixis, Inc., and Regulus Therapeutics, Inc. He is a co-founder of Exelixis, Inc. as well as co-founder and former Chairman of Anadys Pharmaceuticals, Inc. (acquired by Hoffman – La Roche in 2011) and Cellzome, Inc. (acquired by GlaxoSmithKline in 2012). In the not-for-profit sector, in addition to Fondation Santé, he is a member of the Board of Visitors of Duke Health, and a member of the Global Advisory Board of the Duke Institute for Health Innovation.
Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in 2006 after six years with the firm where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where he was an analyst in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette. For his work as an equity analyst he was elected in the Institutional Investor 1987 All America Research Team. He has also received multiple honors and awards for his work in the biopharma industry as a company founder, advisor, and financier.
Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University School of Medicine. He maintains his affiliation with NYU as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an M.B.A. in finance, all from New York University.
George A. Scangos, Ph.D.
Dr. George A. Scangos is the chief executive officer and a member of the Board of Directors of Vir. Previously, he was the chief executive officer and a member of the board of directors of Biogen from July 2010 until December 2016. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products.
Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Dr. Scangos served as the Chair of PhRMA from March of 2016 to January of 2017. He also served as the chair of the California Healthcare Institute in 2010 and was a member of the board of the Global Alliance for TB Drug Development until 2010. He is a member of the boards of trustees of the Boston Museum of Science and the Biomedical Science Careers Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine.
Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos holds a B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.
Katerina Artavanis-Tsakonas, Ph.D.
Dr. Katerina Artavanis-Tsakonas is a Lecturer in Parasitology and Head of Division of Microbiology & Parasitology in the Department of Pathology at the University of Cambridge. Her laboratory studies the interaction between host and pathogen, specifically looking at intracellular parasites and what their tissue adaptations can . . .
Dr. Katerina Artavanis-Tsakonas is a Lecturer in Parasitology and Head of Division of Microbiology & Parasitology in the Department of Pathology at the University of Cambridge. Her laboratory studies the interaction between host and pathogen, specifically looking at intracellular parasites and what their tissue adaptations can reveal about host cell biology.
She established her laboratory at Imperial College London as a Wellcome Trust Fellow from 2009-2015.
Prior to her fellowship, Dr. Artavanis-Tsakonas did her post-doctoral training at Harvard and at the Whitehead Institute, MIT. Dr. Artavanis-Tsakonas received a B.A. in Fine Arts from Yale University in 1996, a M.Phil. in Infectious Disease Epidemiology from Yale School of Medicine in 1998 and a Ph.D. in Immunology from the London School of Hygiene & Tropical Medicine in 2003.
Prior to her academic career, Dr. Artavanis-Tsakonas served as an Assistant Vice President in the Equity Research Department of PaineWebber Inc.
Jason Fisherman, M.D.
Dr. Jason Fisherman is a venture investor, drug developer, and company founder. He began his career in venture capital in 1994 at the global private equity firm Advent International, specializing in biotechnology, pharmaceuticals, and medical technology, becoming a Managing Director in 2002. He co-founded Synthesis Capital in 2007 to . . .
Dr. Jason Fisherman is a venture investor, drug developer, and company founder. He began his career in venture capital in 1994 at the global private equity firm Advent International, specializing in biotechnology, pharmaceuticals, and medical technology, becoming a Managing Director in 2002. He co-founded Synthesis Capital in 2007 to continue investing in a portfolio of innovative science-driven companies. In 2016, he led the start-up C4 Therapeutics as Chief Executive Officer, a Dana-Farber Cancer Institute spin-out building a platform for the design of targeted protein-degrading drugs.
Prior to 1994, Dr. Fisherman spent over ten years in novel drug research and clinical development in biotech, academia, and the National Cancer Institute. While at the NCI, he led the development of Taxol (paclitaxel) from Phase 1b to Phase 3, and in industry he led the development of Oncaspar (PEGaspargase) for leukemia and Adagen (PEGademase bovine) for a rare immunologic orphan disease.
During his venture career, Dr. Fisherman has been responsible for thirty investments, acting as lead/co-lead in most and holding numerous public and private corporate directorships. His investee companies have initiated global clinical studies of over two dozen potential medicines and medical products, and received over ten new product approvals. These companies include Mitotix (merged with GPC Biotech NM:GPC), Exelixis (EXEL), ILEX Oncology (ILXO, acquired by Genzyme), Cubist Pharmaceuticals (CBST, acquired by Merck), Array BioPharma (ARRY), Achillion Pharmaceuticals (ACHN), Crucell (Nasdaq/Euronext:CRXL, acquired by Johnson and Johnson), deCode (DCGN, acquired by Amgen), CV Therapeutics (CVTX, acquired by Gilead), Anadys Pharmaceuticals (ANDS, acquired by Roche), Gamera Biosciences (acquired by Tecan Group), Aegerion Pharmaceuticals (AEGR, acquired by QLT/Novelion), Cellzome (acquired by GlaxoSmithKline), Managed Healthcare Associates (MHA, last acquired by Roper Technologies), Physicians’ Online (acquired by WebMD Health), and Oridion Systems (SW:ORIDN, acquired by Covidien).
A medical oncologist by training, Dr. Fisherman currently serves as a director of Achillion Pharmaceuticals and several private companies, on the Visit Committee of the Dana Farber Cancer Institute, and the board of Fondation Santé. He received a B.A. in Molecular Biophysics and Biochemistry from Yale University, an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School of the University of Pennsylvania.
Jean-François Formela, M.D.
Dr. Jean-Francois Formela is a partner at Atlas Venture, where he focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and . . .
Dr. Jean-Francois Formela is a partner at Atlas Venture, where he focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio, which he co-founded.
Dr. Formela has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), Cellzome (acquired by GlaxoSmithKline), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP).
Dr. Formela joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas he worked at Schering-Plough, where he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
He is a member of the MGH Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.
Edith Heard, Ph.D.
Professor Edith Heard, a geneticist, is director General of the European Molecular Biology Laboratory (EMBL) and is Professor of Epigenetics and Cellular Memory at the College de France and. Before joining the EMBL she was director of the Genetics and Developmental Biology Department at the Institut Curie, Paris. She did her undergraduate work at Cambridge University and earned her Ph.D. at the ICRF (London). During her post-doc at …
Professor Edith Heard, a geneticist, is director General of the European Molecular Biology Laboratory (EMBL) and is Professor of Epigenetics and Cellular Memory at the College de France and. Before joining the EMBL she was director of the Genetics and Developmental Biology Department at the Institut Curie, Paris. She did her undergraduate work at Cambridge University and earned her Ph.D. at the ICRF (London). During her post-doc at the Pasteur Institute in Paris, she began her work on mammalian X-chromosome inactivation and the role and regulation of the Xist non-coding RNA.
Her laboratory continues to focus on epigenetic processes in mammals, with particular interest in the role of non-coding RNAs, nuclear organization, and chromatin structure in the establishment and maintenance of differential expression patterns during early development and in disease. Her pioneering work has been recognized by numerous awards, most recently the Grand Prix INSERM and the Prize of the European Society of Human Genetics.
Professor Heard is a Fellow of the Royal Society and an EMBO member.
Mark Kessel, Esq.
Mark Kessel co-founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies. He is widely recognized as a leader in structuring product development investments for the biopharmaceutical industry. Mr. Kessel was formerly the managing partner of . . .
Mark Kessel co-founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies. He is widely recognized as a leader in structuring product development investments for the biopharmaceutical industry. Mr. Kessel was formerly the managing partner of Shearman & Sterling, with day-to-day operating responsibility and is currently of-counsel to the Firm where he co-heads its healthcare practice. He is also the Chairman of the Foundation for Innovative New Diagnostics (FIND), an Editorial Advisor to Nature Biotechnology and a director of Organovo.
Mr. Kessel previously served on strategic advisory committees of biotechnology companies, as a director of the Global Alliance for TB Drug Development, the Biotechnology Industry Organization, Dynavax Technologies Corporation, OXiGENE, Inc., Antigenics, Inc., Heller Financial Inc., and Harrods (UK) Limited. He has also served as a Trustee of the Museum of the City of New York and on the advisory committee of the Mt. Sinai Rape Crisis Center. He has written on the biotech industry and on world health for Nature Reviews Drug Discovery, Nature Biotechnology, The Lancet, The Scientist, Science Translational Medicine, Start-Up, BioCentury and other publications and on issues related to governance for such publications as The Wall Street Journal, Financial Times, The Deal, NACD Directorship, BNA’s Corporate Counsel Weekly, Bloomberg BNA, Corporate Law & Accountability Report and Euromoney. He received a B.A. with honors in Economics from the City College of New York and a J.D. magna cum laude from Syracuse University College of Law.
Esperanza B. Papadopoulos, M.D.
Dr. Esperanza Papadopoulos is the Clinical Director of the Adult Bone Marrow Transplantation Inpatient Unit at Memorial Sloan Kettering Cancer Center (MSKCC). She is Member in the department of Medicine at MSKCC and a Professor at the Cornell University Weill College of Medicine. Dr. Papadopoulos joined MSKCC in 1989 and since that time her research and clinical practice have been focused on allogeneic . . .
Dr. Esperanza Papadopoulos is the Clinical Director of the Adult Bone Marrow Transplantation Inpatient Unit at Memorial Sloan Kettering Cancer Center (MSKCC). She is Member in the department of Medicine at MSKCC and a Professor at the Cornell University Weill College of Medicine. Dr. Papadopoulos joined MSKCC in 1989 and since that time her research and clinical practice have been focused on allogeneic bone marrow transplantation. Specifically, her research interests have centered on the use of CD34 selected stem cell transplants to minimize the risk of graft-vs-host disease and also to the use of post-transplant maintenance for prevention of post-transplant relapse.
Prior to MSKCC Dr. Papadopoulos was a Hematology-Oncology Fellow at New York University Medical Center. Dr. Papadopoulos received her medical degree from New York University School of Medicine in 1982 and continued at NYU as an intern, resident and chief resident in Internal Medicine. Dr. Papadopoulos is board certified in Internal Medicine, Hematology and Oncology. Prior to NYU Dr. Papadopoulos completed her undergraduate studies at Fordham University with a double major in biology and philosophy.
In the not-for-profit sector Dr. Papadopoulos is a founding Member of Fondation Santé.
Angeliki Louvi, Ph.D.
Senior Educational Advisor
Dr. Angeliki Louvi is Associate Professor in the Departments of Neurosurgery and Neuroscience at the Yale School of Medicine. Her laboratory studies the molecular and cellular mechanisms governing the development of the mammalian brain and how the perturbation of basic biological processes leads to clinically significant . . .
Dr. Angeliki Louvi is Associate Professor in the Departments of Neurosurgery and Neuroscience at the Yale School of Medicine. Her laboratory studies the molecular and cellular mechanisms governing the development of the mammalian brain and how the perturbation of basic biological processes leads to clinically significant brain pathologies. She is particularly interested in neurovascular and structural brain disorders associated with specific genetic lesions and uses model organisms and stem cell-based assays to gain insight into fundamental neurodevelopmental processes and to provide information relevant for the design of rational therapeutic approaches.
She received a B.Sc. in Biology from the University of Athens, and M.A., M. Phil, and Ph.D. degrees from Columbia University. After post-doctoral work at the Ecole Normale Superieure in Paris and the University of Chicago, she joined Yale in 2005.